Arcus Biosciences (RCUS) Total Liabilities (2016 - 2026)

Arcus Biosciences' Total Liabilities history runs 11 years deep, the most recent figure standing at $473.0 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 29.3% year-over-year to $473.0 million; the TTM figure through Mar 2026 stood at $473.0 million (down 29.3% YoY), while the FY2025 annual figure was $508.0 million, down 23.61% from the prior year.
• Total Liabilities was $473.0 million for Q1 2026 at Arcus Biosciences, down from $508.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $746.8 million in Q1 2022 to a low of $473.0 million in Q1 2026.
• Historically, Total Liabilities has averaged $629.3 million across 5 years, with a median of $654.0 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities surged 176.27% in 2022, then decreased 29.3% in 2026.
• A 5-year view of Total Liabilities shows it stood at $643.0 million in 2022, then declined by 1.56% to $633.0 million in 2023, then rose by 5.06% to $665.0 million in 2024, then decreased by 23.61% to $508.0 million in 2025, then declined by 6.89% to $473.0 million in 2026.
• The last three Total Liabilities figures came in at $473.0 million (Q1 2026), $508.0 million (Q4 2025), and $538.0 million (Q3 2025), per Business Quant data.